MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects

Abstract

The deregulation of several microRNAs (miRNAs) has been associated with neurodegenerative processes, including Parkinson's disease (PD). Our aim was to characterize the level of miRNAs in the substantia nigra (SN) of PD patients and healthy donors. This is an important issue to characterize new putative markers and therapeutic targets for PD. RNA was extracted from the SN of postmortem PD (n=8) and healthy (n=4) subjects, and the level of 733 human miRNAs was assayed with TaqMan low-density arrays (TLDAs). Overall, there was a miRNA downregulation in the SN of patients. The mean level of 11 miRNAs was significantly different (p<0.05) between patients and controls, with 10 downregulated among the patients. MiR-198, -135b, -485-5p, and -548d were the best candidates and were quantified with individual TaqMan assays in the 12 samples. MiR-135b showed the most significant difference between patients and healthy donors. The bioinformatic analysis suggested that this miRNA could bind to genes implicated in several neurodegenerative pathways.

Retracted: Suppression of microRNA‐342‐3p increases glutamate transporters and prevents dopaminergic neuron loss through activating the Wnt signaling pathway via p21‐activated kinase 1 in mice with Parkinson's disease

“…Previous studies showed that PAK1 was regulated by several miRNAs in different cellular activities (Saydam et al, 2011;Zhao et al, 2011). promoter of survival of dopaminergic neurons, was observed downregulated in human PD brains, and miR-7 was found to regulate cell death and oxidative stress, while miR-184 and Let-7 was reported to regulate dopaminergic neuron survival and activity (Cardo et al, 2014). The Wnt signaling pathway controls the survival of neurons, involves in the development of the central nervous system, and monitors the functions of the adult nervous system .…”

MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian

“…More importantly the miR-200a-3p and -144-5p were showed the different expression in PD mice for the first time. Other miRNAs reported by several PD studies, such as miR-133b, -34c-5p, -205,-155, -135b, -212, -495, -193a-3p, -34b/c and -485-5p, shared the similar expression regulation with our result, but their fold-change was lower and didn't meet our inclusion criteria [59, 61–63, 68–70]. However, the miR-214, -124, -132, -127-5p, -146b-5p, and -16-5p reported in other PD models, were not found the different expression [26, 30, 54, 55, 57, 60].…”

“…Our data revealed that more than 644 miRNAs were detected with significant level-change in A53T mice, especially 40 miRNAs with fold-change ≥ 2. Among the 40 miRNAs, miR-542-3p, -10a-5p, -10b-3p, -141, -200b-3p, -542-3p, and -505-5p were confirmed with similar fluctuation of expression as reports [26, 30, 66–68]. More importantly the miR-200a-3p and -144-5p were showed the different expression in PD mice for the first time.…”

Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples

“…The increased levels of miR‐338‐3p, miR‐30e‐3p, and miR‐30a‐3p and decreased levels of miR‐16‐2‐3p and miR‐1294 were detected (Burgos et al., 2014). In another study (Cardo et al., 2014), miR‐135b showed the most significant difference between patients and healthy donors. For the blood miRNAs in PD, Margis et al.…”

“…Although the aberrant expression of miRNAs was reported frequently in PD‐diagnosed patients (Cardo et al., 2014; Filatova et al., 2012; Hoss et al., 2016), the circulating miRNA pattern in PD has not been well defined yet. Burgos et al.…”